Browse grants
Federal opportunities with plain-English eligibility summaries. We aggregate public records — always verify the details on the funder’s site before applying.
NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research
Due Sep 30, 2026Naval Research Laboratory · $0
The Naval Research Laboratory's Long Range BAA supports basic and applied research across many scientific and technical disciplines, including systems, materials science, ocean and atmospheric science, and space technology. Eligibility is described as unrestricted (open to any entity type), subject to clarifications in the announcement. No specific award amount is stated. Applicants typically submit white papers first; review the full announcement for topic areas and submission steps.
ResearchersSmall businessSchools & universitiesBroad eligibilityDoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award
Due Sep 30, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
This Department of War (Defense Health Agency) ALS Research Program Pilot Clinical Trial Award supports rapid implementation of phase 1 to small-scale phase 2 trials affecting ALS treatment or management. Eligibility is described as unrestricted (open to any entity type), subject to clarifications. Applications must address biomarker-driven interventions or clinical care, incorporate community collaboration, and include a regulatory strategy and transition plan. No specific award amount is stated.
ResearchersSchools & universitiesBroad eligibilityDoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award
Due Sep 30, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
This Department of War (Defense Health Agency) ALS Research Program Clinical Outcomes and Biomarkers Award supports development and validation of clinical outcomes and biomarkers to enrich ALS clinical trials. Eligibility is described as unrestricted (open to any entity type), subject to clarifications. Projects may target a specific therapy, therapeutic class, or ALS subtype and may use digital health measures. Community collaboration informed by the ALS lived-experience community is expected. No specific award amount is stated.
ResearchersSchools & universitiesBroad eligibilityDoW Breast Cancer, Breakthrough Award Level 3
Due Sep 30, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
This Department of War (Defense Health Agency) Breast Cancer Research Program Breakthrough Award Level 3 supports promising research with high potential to lead to breakthroughs in breast cancer. Eligibility is described as unrestricted (open to any entity type), subject to clarifications. Small-scale clinical trials are allowed but not required, and the research team must include two or more breast cancer consumer advocates. No specific award amount is stated; applications must address an FY26 BCRP overarching challenge.
ResearchersSchools & universitiesBroad eligibilityDoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award
Due Sep 30, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
This Department of War (Defense Health Agency) ALS Research Program Therapeutic Development Award supports research from preclinical validation of therapeutic leads through FDA IND-enabling studies, with product-driven, empirical projects. Eligibility is described as unrestricted (open to any entity type), subject to clarifications. Applicants must begin with lead compounds in hand and already-demonstrated proof-of-concept efficacy in a preclinical ALS model; candidates already granted an IND are not appropriate. No specific award amount is stated.
ResearchersSchools & universitiesBroad eligibilityDoW Breast Cancer, Breakthrough Award Level 4
Due Sep 30, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
This Department of War (Defense Health Agency) Breast Cancer Research Program Breakthrough Award Level 4 supports promising research with high potential for breakthroughs in breast cancer. Eligibility is described as unrestricted (open to any entity type), subject to clarifications. Clinical trials are required for this level, and the research team must include two or more breast cancer consumer advocates. Up to two partnering Principal Investigators are allowed. No specific award amount is stated; applications must address an FY26 BCRP overarching challenge.
ResearchersSchools & universitiesBroad eligibilityCooperative Agreement for In Vivo High-Resolution Imaging for Inner Ear Visualization (U01 Clinical Trial Required)
Due Oct 1, 2026National Institutes of Health · Up to $500K
This NIH (NIDCD) U01 cooperative agreement funds high-risk clinical trials developing in vivo high-resolution imaging technologies for the living human inner ear; a clinical trial is required for this mechanism. Eligible applicants include a broad range of domestic and foreign organizations such as higher-education institutions (including minority-serving institutions), tribal governments, faith-based or community organizations, and U.S. territories. The stated maximum is about $500,000. A multidisciplinary team approach is encouraged; review the RFA for full eligibility details.
ResearchersSchools & universitiesGovernment / tribalLarge award+1 moreIn Vivo High-Resolution Imaging for Inner Ear Visualization (R01 Clinical Trial optional)
Due Oct 1, 2026National Institutes of Health · Up to $500K
This NIH (NIDCD) R01 award funds development of in vivo high-resolution structural and functional imaging technologies for the living human inner ear. A wide range of domestic and foreign organizations may apply, including higher-education institutions (including minority-serving institutions), tribal governments, faith-based or community organizations, and U.S. territories. A clinical trial is optional. The stated maximum is about $500,000, and a multidisciplinary team approach is encouraged; review the RFA for full eligibility details.
ResearchersSchools & universitiesGovernment / tribalLarge award+1 moreDoW Ovarian Cancer, Clinical Trial Award
Due Oct 1, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
This Department of War (Defense Health Agency) Ovarian Cancer Clinical Trial Award supports rapid implementation of clinical trials with potential to significantly affect ovarian cancer treatment or management. Eligibility is described as unrestricted (open to any entity type), subject to clarifications in the announcement. Trials may range from small proof-of-concept studies through large-scale efficacy trials. No specific award amount is stated; review the full funding opportunity for requirements.
ResearchersSchools & universitiesBroad eligibilityDoW, Ovarian Cancer, Pilot Award
Due Oct 1, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
This Department of War (Defense Health Agency) Ovarian Cancer Pilot Award supports research exploring innovative concepts or theories that could expand or modify current thinking in ovarian cancer. Eligibility is described as unrestricted (open to any entity type), subject to clarifications. Innovation is central; preliminary data are not required but allowed. A blinded pre-application screening means no PI, collaborator, or organization identifying material should be included at that stage. No specific award amount is stated.
ResearchersSchools & universitiesBroad eligibilityEDU Core Research
Due Oct 1, 2026U.S. National Science Foundation · $500K–$2.5M
NSF's EDU Core Research (ECR:Core) program supports fundamental research advancing knowledge of STEM learning, broadening participation, and STEM workforce development for learners of all ages in formal and informal settings. Eligibility is described as unrestricted (open to any entity type), subject to clarifications in the solicitation. Funding has three levels: up to $500,000 (Level I), up to $1.5 million (Level II), and up to $2.5 million (Level III), with project durations of three to five years.
ResearchersSchools & universitiesLarge awardBroad eligibilityDoW, Ovarian Cancer, Investigator-Initiated Research Award
Due Oct 1, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
This Department of War (Defense Health Agency) Ovarian Cancer Investigator-Initiated Research Award supports high-impact research from basic laboratory through translational work, excluding clinical trials. Eligibility is described as unrestricted (open to any entity type), subject to clarifications. Preliminary data are required, and a Partnering PI option allows two investigators to work synergistically on a single project. No specific award amount is stated; review the full opportunity for requirements.
ResearchersSchools & universitiesBroad eligibilityDoW, Peer Reviewed Cancer, Impact Award
Due Oct 5, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
This Department of War (Defense Health Agency) Peer Reviewed Cancer Research Program Impact Award supports mature research with near-term potential to affect clinical cancer care within congressionally directed FY26 topic areas. Eligibility is described as unrestricted (open to any entity type), subject to clarifications. Applications must include preliminary data supporting feasibility; clinical trials are allowed. Up to two partnering Principal Investigators are permitted. No specific award amount is stated.
ResearchersSchools & universitiesBroad eligibilityDoW Peer Reviewed Cancer, Idea Award
Due Oct 5, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
This Department of War (Defense Health Agency) Peer Reviewed Cancer Research Program Idea Award supports innovative, untested, high-risk/high-reward concepts and basic cancer research relevant to the Military Health System. Eligibility is described as unrestricted (open to any entity type), subject to clarifications. Preliminary data are not required, but a strong scientific rationale is. A new Early Career Investigator option supports promising investigators early in faculty appointments. No specific award amount is stated.
ResearchersSchools & universitiesBroad eligibilityDoW Peer Reviewed Cancer, Clinical Trial Award
Due Oct 5, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
This Department of War (Defense Health Agency) Peer Reviewed Cancer Research Program Clinical Trial Award funds clinical trials (phase 0 through phase III) testing new products, drugs, devices, or approaches to treat or manage cancer within designated topic areas. Applications must include a clinical trial and patient advocates, animal studies are not allowed, and any required IND/IDE regulatory application must be submitted by the application deadline. Eligibility is described as unrestricted (open to any standard entity type), subject to clarification in the program announcement. No specific award amount is stated in this record.
ResearchersSchools & universitiesBroad eligibilityAdvancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trail Required)
Due Oct 6, 2026National Institutes of Health · Amount varies
This NIH R01 funds research examining the efficacy and clinical effectiveness of digital health technologies for the remote management of type 2 diabetes; a clinical trial is required. Eligible applicants include federal agencies, tribal governments, faith- or community-based organizations, regional organizations, and U.S. territories, in addition to standard research institutions. Foreign organizations and the foreign components of U.S. organizations are not eligible, and foreign components are not allowed. No specific award amount is stated in this record; see the NOFO for full eligibility details.
NonprofitsResearchersSchools & universitiesGovernment / tribal+1 moreDoW Pancreatic Cancer Research Program, Focused Pilot Award
Due Oct 7, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
This Department of War (Defense Health Agency) Pancreatic Cancer Research Program Focused Pilot Award supports exploratory, innovative pancreatic cancer research intended to produce preliminary data for future work; preliminary data are allowed but not required. Clinical research studies are permitted, but clinical trials are not allowed and preclinical animal-only studies do not meet the intent. Eligibility is described as unrestricted (open to any standard entity type), subject to clarification in the program announcement. No specific award amount is stated in this record.
ResearchersSchools & universitiesBroad eligibilityDoW Pancreatic Cancer Research Program, Idea Development Award
Due Oct 7, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
This Department of War (Defense Health Agency) Pancreatic Cancer Research Program Idea Development Award funds innovative, high-risk/high-reward pancreatic cancer research; preliminary data relevant to the project are required. Clinical research studies are allowed, but clinical trials are not. Eligibility is described as unrestricted (open to any standard entity type), subject to clarification in the program announcement. An optional partnering mechanism offers higher funding to pair an experienced PI with an early-career investigator. No specific award amount is stated in this record.
ResearchersSchools & universitiesBroad eligibilityDoW Pancreatic Cancer Research Program, Translational Research Partnership Award
Due Oct 7, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
This Department of War (Defense Health Agency) Pancreatic Cancer Research Program Translational Research Partnership Award funds partnerships among clinicians, population, applied, and/or basic scientists to move promising pancreatic cancer ideas toward clinical application, and requires two Principal Investigators (an initiating and a partnering PI) with at least one having pancreatic cancer expertise. Preliminary data are required; pilot clinical trials and retrospective/correlative studies are allowed, but large-scale clinical trials are not. Eligibility is described as unrestricted (open to any standard entity type), subject to clarification in the program announcement. No specific award amount is stated.
ResearchersSchools & universitiesBroad eligibilityOptimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)
Due Oct 9, 2026National Institutes of Health · Up to $1M
This NIH (NIDDK) U01 cooperative agreement funds clinical centers to join a consortium testing anti-obesity medication treatment strategies for children and adolescents with obesity. A clinical trial is required, and as a cooperative agreement NIH staff are substantially involved; applicants are typically clinical research institutions. Foreign organizations, the foreign components of U.S. organizations, and foreign components generally are not eligible or allowed. Stated funding is up to about $1,000,000; consult the NOFO for full eligibility details.
ResearchersSchools & universitiesLarge awardBroad eligibility